Muhammad Amanullah | August 13, 2026
THE TURE POST (Web News) — New scientific research into popular weight-loss medications such as Ozempic and Wegovy has highlighted another potential benefit of these drugs.
Researchers say the medications may not only reduce appetite and body weight but could also help decrease cravings for alcohol and certain other addictive substances.
These medications belong to a class known as GLP-1 agonists. They were initially developed to treat Type 2 diabetes and later became widely used in the treatment of obesity because of their weight-loss effects.
How Do GLP-1 Medications Work?
GLP-1 medications mimic the effects of a naturally occurring hormone in the body. They help regulate insulin release and slow digestion, which can make people feel full for longer periods.
As a result, many people taking these medications experience reduced appetite and weight loss.
Scientists are now also investigating how these medications may affect the brain.
Possible Effects on the Brain’s Reward System
Research suggests that GLP-1 medications may affect more than the systems responsible for controlling hunger.
They may also influence areas of the brain involved in creating cravings for foods and substances that people find pleasurable.
When a person thinks about something they enjoy, certain chemical processes in the brain can encourage them to seek out and consume it. If this reward system becomes excessively active, it may contribute to obesity, problematic alcohol use and other forms of addiction.
Reduced Alcohol Cravings
Early research has produced evidence suggesting that some people taking GLP-1 medications may consume less alcohol.
Scientists believe one possible explanation is that these medications could reduce the rewarding or pleasurable effects associated with addictive substances by influencing the brain’s reward system.
However, researchers emphasize that more comprehensive human studies are needed to determine how strong and long-lasting these effects may be.
Research Into Other Addictive Substances
Scientists are investigating potential effects beyond alcohol.
Early animal studies have examined whether GLP-1 medications could influence the use or cravings associated with substances including cocaine, amphetamines, opioids and nicotine.
However, experts caution that findings from animal studies cannot automatically be applied to humans. More human clinical trials will therefore be necessary before these medications can be considered as a potential treatment for addiction.
A New Area of Research
Scientists say there are some similarities between obesity and addiction at the brain level because both can involve neural systems associated with craving, pleasure and reward.
If future research confirms that GLP-1 medications can effectively reduce addictive cravings, the drugs could eventually become an important area of research beyond obesity and diabetes.
For now, however, experts say it would be premature to consider GLP-1 medications an established alternative treatment for addiction. More clinical research is needed to determine their potential benefits, risks and long-term effects.
